India has four more COVID-19 vaccines in Pipeline

The Drug Controller General of India(DCGI) has given Emergency Use Authorization (EUA) to the Two vaccines on the basis of safety and immunogenicity, COVISHIELD from Serum Institute of India (SII) & COVAXIN of Bharat BioTech (BBIL). The Government of India has purchased 110 lakh vaccines from SII at the cost of Rs.200/dose(excluding taxes) and 55 lakh Vaccines of COVAXIN are being procured from BBIL. The cost of 38.5 lakh doses is Rs 296/dose (excluding taxes).

The other vaccines that are in the pipeline are Zydus Cadila that has completed Phase-2 clinical rials and will be starting Phase -3 trials, Sputnik V Phase-2 & 3 trials ongoing, Biological E Phase -1 trails ongoing and Gennova Phase -1 trials approved.

Recommended For You